In systemic HCC therapy, the combination of immune checkpoint inhibitors, and VEGF pathway inhibitors such as sorafenib could promote an immune-permissive environment, thereby enhancing the response to immune therapeutic approaches. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.